Table 1.
The demographic characteristics of the study group.
| Total (n = 95) | BNT162b2 Group (n = 70) | CoronaVac Group (n = 25) | |
|---|---|---|---|
| Median age (IQR *) Age group (n/%) 18–29 30–39 40–49 50–59 >60 |
56 (42–63) 9 (9.5) 12 (12.6) 18 (18.9) 24 (25.3) 32 (33.7) |
56.5 (43–65) 6 (8.6) 9 (12.9) 13 (18.6) 16 (22.9) 26 (37.1) |
52 (39.5–60) 3 (12.0) 3 (12.0) 5 (20.0) 8 (32.0) 6 (24.0) |
| Female gender (n/%) | 28 (29.5) | 24 (34.3) | 4 (16.0) |
| Type of transplantation (n/%) SOT ** Liver Kidney HSCT *** Autologous Allogeneic |
69 (72.6) 52 (54.7) 17 (17.9) 26 (27.4) 21 (22.1) 5 (5.3) |
49 (70.0) 38 (54.3) 11 (15.7) 21 (30.0) 16 (22.9) 5 (7.1) |
20 (80.0) 14 (56.0) 6 (24.0) 5 (20.0) 5 (20.0) 0 (0) |
| Median time after transplantation-years (IQR) | 4 (2–6) | 4 (2–6) | 4 (3–6) |
| Time after the booster dose (n/%) <6 months ≥6 months |
82 (86.3) 13 (13.7) |
60 (85.7) 10 (14.3) |
22 (88.0) 3 (12.0) |
| Antimetabolite usage for SOT (n/%) | 28 (40.6) | 23 (32.9) | 5 (20.0) |
* Interquartile range; IQR; ** Solid organ transplantation; SOT; *** Hematopoietic stem cell transplantation; HSCT.